The susceptibilities of recent clinical isolates of anaerobic bacteria from two community hospitals were determined. Thirty percent of pigmented Bacteroides species and bile-sensitive, nonpigmented Bacteroides species produced penicillinase and were resistant to amoxicillin. Cefoxitin and clindamycin showed good activity against most strains, with the exception of rare isolates of the Bacteroides fragilis group and some strains of Clostridium species. While amoxicillin was not active against B. fragilis and other members of the B. fragilis group, amoxicillin-clavulanic acid was very active against almost all of these organisms. Imipenem was the most potent agent against all strains tested.
The increasing incidence of resistance in a variety of anaerobic bacteria to available antimicrobial agents has been noted elsewhere (3, 6, 12) . Bacteroides strains, other than of the B. fragilis group, resistant to penicillin and strains of the B. fragilis group resistant to cefoxitin and clindamycin have been noted (6, 12) . Penicillin resistance of species other than B. fragilis has also been correiated with clinical therapeutic failure (4) .
Data on the in vitro activities of newer beta-lactam antimicrobial agents against anaerobic bacteria have come from large university and research centers (1, 2, 6, 9) . Since there is clustering of resistance and regional differences in resistance patterns, it is difficult to extrapolate published data to those clinical situations encountered at community hospitals. Most community hospital clinical microbiology laboratories do not perform susceptibility studies on anaerobic bacteria. Community hospitals often have patient populations and antibiotic usage patterns different from those of university and research centers.
To determine the relevance and potential utility of these agents to the community setting, we compared the activities of amoxicillin-clavulanic acid and, imipenem with amoxicillin, cefoxitin, piperacillin, moxalactam, and clindamycin against anaerobic bacteria isolated from patients in community hospitals.
The 204 strains of anaerobic bacteria studied (Table 1) were recent clinical isolates from two primary-care community hospitals (Santa Monica Hospital Medical Center and St. John's Hospital Health Center, Santa Monica, Calif.). All isolates were identified by standard criteria (7, 11 The susceptibilities of isolates were determined by an agar dilution method (11) . Before being tested, the isolates were grown overnight in thioglycolate 135C medium supplemented with vitamin K1, hemin, and a marble chip (CalScott, Carson, Calif.). Occasional fastidious strains required additional supplementation with Fildes enrichment (Difco Laboratories, Detroit, Mich.) or formate-fumurate solution (11) . The turbidity of growth was adjusted to one-half McFarland standard no. 1 with brucella broth that had been steamed for 10 mim on the day of use. Antimicrobial agent solutions were prepared on the day of study and were incorporated into brucella agar supplemented with vitamin K1, hemin, and 5% laked sheep blood to yield final concentrations of 256 to 0.06 p.g/ml. The No high-grade cefoxitin resistance was encountered. Clindamycin was active against most isolates, with occasional strains of the B. fragilis group displaying resistance. The activity of piperacillin was similar to that of ampicillin.
Moxalactam had an intermediate level of activity. Clavulanic acid inhibits the activity of many betalactamases, including those produced by B. fragilis (1, 9) . Our study showed that amoxicillin-clavulanic acid was very active against most strains tested, including amoxicillinresistant Bacteroides species, B. fragilis, and other B. fragilis group strains. Our community hospital isolates had a 30% resistance rate for non-B. fragilis group species. Our susceptibility results for other isolates are similar to the data reported by others (1, 9, 10) from university and research centers. Although clinical data on the therapy of infections involving anaerobic bacteria are sparse (5), our data suggest that amoxicillin-clavulanic acid may be useful as a single agent in the treatment of mixed infections.
Imipenem is a carbapenem antibiotic with a broad spectrum of activity and is coadministered with cilastatin, a renal dehydropeptidase I inhibitor. Our study showed it to exhibit potent activity against virtually all of the community anaerobic strains tested. This finding is in accord with other studies that noted imipenem to be more active than metronidazole, clindamycin, and chloramphenicol against the B. fragilis group (2, 8) .
Of particular concern was the 30% rate of resistance to penicillin of the pigmented and nonpigmented, bile-sensitive Bacteroides species. The current policy of many community hospitals to limit susceptibility studies to B. fragilis group isolates should be reconsidered. As a minimum, testing for the presence of P-lactamase should be performed with these organisms.
(These data were presented in part at the 14th International Congress of Chemotherapy, Kyoto, Japan, 23 to 28 June 1985.)
